$3,802.29 travel Payment -- Merck & Co to Dr. Laura Hall
Cardiologist Receives $3,802.29 in Travel Payments from Merck & Co. for Skyrizi
This page provides a detailed analysis of a $3,802.29 travel payment from Merck & Co to Dr. Laura Hall. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $3,802.29 |
| Payment Type | travel |
| Payment Nature | Travel and Lodging |
| Pharmaceutical Company | Merck & Co |
| Physician | Dr. Laura Hall |
| NPI Number | 1288881679 |
| Physician Specialty | Cardiology |
| Location | City, MD |
| Date of Payment | 2025-03-16 |
| Related Drug/Device | Skyrizi |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Merck & Co made a $3.8K travel payment to Laura Hall, a Cardiology specialist in City, MD. The payment was associated with Skyrizi. The payment of $3,802.29 to Dr. Laura Hall from Merck & Co. for travel and lodging related to Skyrizi is a significant amount for a single payment. The payment occurred on March 16, 2025, indicating a recent engagement between the pharma company and the cardiologist. The specific nature of the travel and lodging is not detailed, leaving room for interpretation regarding its purpose.
Patient Guidance: What This Payment Means for You
This payment may cover expenses for educational events or professional development related to a medication. It's advisable to inquire about the specific purpose of the travel if you have concerns. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Travel and lodging payments to cardiologists can vary widely depending on the nature of the engagement, such as attending major medical conferences or participating in advisory boards. This amount may be within the typical range for such activities.
Regulatory Context: Sunshine Act Requirements
Payments for travel and lodging are reportable under the Sunshine Act, provided they are made by applicable manufacturers or GPOs to physicians or teaching hospitals. The purpose of the payment should be clearly documented.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- travel-and-lodging
- cardiologist
- merck-and-co
- skyrizi
- open-payments
Understanding travel Payments
Travel and lodging payments cover transportation and accommodation expenses for physicians attending conferences, advisory board meetings, or speaking engagements sponsored by pharmaceutical companies. These payments can be substantial, particularly for international travel or multi-day events.
Frequently Asked Questions About This Payment
What was this $3.8K payment for?
This was a travel payment of $3.8K from Merck & Co to Laura Hall, categorized as "Travel and Lodging". It was associated with Skyrizi. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Laura Hall accept pharmaceutical money?
Yes, Laura Hall received this $3.8K payment from Merck & Co. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Laura Hall's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this travel payment?
A travel payment of $3.8K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Cardiology?
To compare this payment against Cardiology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Cardiology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Laura Hall's relationship with Merck & Co?
The payment covers 'Travel and Lodging', suggesting expenses incurred for attending events, conferences, or site visits. This $3.8K travel payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Cardiology?
The amount is substantial for a single travel payment, potentially covering multiple days or extensive travel.
What should patients do after learning about this payment?
This payment may cover expenses for educational events or professional development related to a medication. It's advisable to inquire about the specific purpose of the travel if you have concerns.
What else should I know about this travel payment?
The payment is linked to 'Skyrizi', a specific drug, indicating a focused relationship with this product.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.